A Randomized, Dose-controlled, Open-label, Parallel, 2-treatment Group, Single Center, Pilot Study to Evaluate the Effectiveness of Sarpogrelate on Blood Hyperviscosity in the Patients With Peripheral Arterial Disease
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Sarpogrelate (Primary)
- Indications Arterial occlusive disorders; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Yuhan
- 21 Oct 2019 Planned End Date changed from 1 Oct 2019 to 1 Apr 2020.
- 21 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.